CorMedix, a biopharmaceutical company specialising in critical care products, is to acquire Melinta Therapeutics for $300m.

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.

Astria has made an exclusive licensing agreement with Kaken for the development and commercialisation rights of navenibart in Japan.

The US FDA has given accelerated approval to Jazz Pharma for Modeyso to treat adult and paediatric patients with diffuse midline glioma.

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.